• Active, not recruiting

NCT04552743: Phase 2: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for ASCT

Updated: May 24

NCT04552743: Phase 2: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

MGTA145

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma


This research study tests a new medicine for mobilizing stem cells so they can be collected and used for autologous stem cell transplant for treatment of multiple myeloma. MGTA-145, the new medicine, will be given with plerixafor.


Sponsor

Stanford University

 

ClinicalTrials.gov Identifier: NCT04552743


Official Title: Phase II Study of MGTA-145 in Combination With Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Patients With Multiple Myeloma

First Posted : September 17, 2020


Click here to see details on ClinicalTrials.gov

 

Drug: MGTA-145

Drug: Plerixafor

 

MGTA-145


CXCR2 Agonist MGTA-145 (Code C176851)

CXCR2 Agonist MGTA-145

GRO-beta

GROb

MGTA 145

MGTA-145

MGTA145


 

Location

United States, California


Posts Archive